Murphy Capital Management Inc. Sells 1,520 Shares of iShares US Pharmaceuticals ETF (IHE)

Murphy Capital Management Inc. trimmed its holdings in shares of iShares US Pharmaceuticals ETF (NYSEARCA:IHE) by 5.7% during the 1st quarter, HoldingsChannel reports. The fund owned 24,956 shares of the company’s stock after selling 1,520 shares during the period. Murphy Capital Management Inc.’s holdings in iShares US Pharmaceuticals ETF were worth $3,842,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. PNC Financial Services Group Inc. grew its stake in shares of iShares US Pharmaceuticals ETF by 26.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 364 shares of the company’s stock worth $51,000 after purchasing an additional 77 shares during the last quarter. Oppenheimer & Co. Inc. raised its holdings in shares of iShares US Pharmaceuticals ETF by 4.2% during the fourth quarter. Oppenheimer & Co. Inc. now owns 2,241 shares of the company’s stock valued at $315,000 after purchasing an additional 90 shares during the period. Advisor Group Inc. raised its holdings in shares of iShares US Pharmaceuticals ETF by 7.4% during the fourth quarter. Advisor Group Inc. now owns 2,318 shares of the company’s stock valued at $326,000 after purchasing an additional 160 shares during the period. Liberty Wealth Management LLC acquired a new position in shares of iShares US Pharmaceuticals ETF during the fourth quarter valued at about $29,000. Finally, Private Advisor Group LLC raised its holdings in shares of iShares US Pharmaceuticals ETF by 19.2% during the fourth quarter. Private Advisor Group LLC now owns 1,686 shares of the company’s stock valued at $237,000 after purchasing an additional 271 shares during the period.

Shares of NYSEARCA IHE traded down $1.05 during trading on Thursday, hitting $151.35. 1,100 shares of the company traded hands, compared to its average volume of 10,716. iShares US Pharmaceuticals ETF has a fifty-two week low of $131.91 and a fifty-two week high of $170.26.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 26th. Stockholders of record on Thursday, March 21st were issued a dividend of $0.5565 per share. The ex-dividend date was Wednesday, March 20th. This represents a $2.23 annualized dividend and a dividend yield of 1.47%. This is a positive change from iShares US Pharmaceuticals ETF’s previous quarterly dividend of $0.35.

COPYRIGHT VIOLATION WARNING: This report was originally published by WKRB News and is the property of of WKRB News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.wkrb13.com/2019/04/11/murphy-capital-management-inc-sells-1520-shares-of-ishares-us-pharmaceuticals-etf-ihe.html.

About iShares US Pharmaceuticals ETF

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.

Featured Story: What is an investor looking for in an SEC filing?

Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares US Pharmaceuticals ETF (NYSEARCA:IHE).

Institutional Ownership by Quarter for iShares US Pharmaceuticals ETF (NYSEARCA:IHE)

Receive News & Ratings for iShares US Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares US Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.